Antimicrobial resistance (AMR) is a global threat with potentially devastating consequences to those infected with resistant pathogens and high direct and indirect cost to society. In the future, lack of effective antibiotics could make routine medical interventions extremely dangerous and make other more complex interventions and procedures impossible. For these reasons, AMR must be regarded as a global, regional, and national priority for health organizations and governments.
Shionogi is a co-signatory of the January 2016 Davos Declaration. This document, signed by >100 companies and trade associations, called for collective action to create a sustainable and predictable market for antibiotics, vaccines, and diagnostics whilst emphasising the need for conservation of new and existing treatments. Together with 12 other leading companies, Shionogi has gone further, signing an Industry Roadmap that includes action plans for antibiotic research and science, appropriate use, access, and manufacturing and environmental actions to achieve this goal.
Successfully addressing AMR requires coordinated action by all stakeholders, including governments and international organizations, the pharmaceutical industry, and prescribers and users of antibiotic products. Shionogi believes that the following actions are required:
- Create a predictable and sustainable market for AMR products through economic incentives, such as pull incentives and new value assessments for reimbursement
- Harmonize global regulations for development and approval of new antibiotics
- Establish clinical trial networks to help execute clinical studies more efficiently
- Ensure appropriate use of antibiotics through regulation of animal use, stewardship, and timely surveillance of resistance epidemiology
- Make effective medicines available for patients in need directly or via alliance partners
- Reduce environmental impact from manufacture of antibiotics
We are proud of our on-going commitment to the research and development of new antimicrobial therapies, and we are working hard to ensure that both individual patients and society as a whole will continue to benefit from effective AMR drugs. We call on all stakeholders to join the fight against AMR.